Prostate Cancer Daily

June 24, 2026

Videos

Peer-to-Peer Clinical Conversations

Radiopharmaceuticals in Prostate Cancer Part 4B: Payloads, Carriers, Targets, and Combinations - Michael Morris & Rana McKay

Michael J. Morris

Michael Morris and Rana McKay discuss isotope and carrier selection, combination strategies, and emerging targets in radiopharmaceutical therapy with Philip Kantoff.

View

PARP Inhibitors in Prostate Cancer: A Decade of Development and the Combination vs Monotherapy Debate for HRR-Mutated Disease - Neeraj Agarwal

Neeraj Agarwal

Pedro Barata interviews Neeraj Agarwal about PARP inhibitors in prostate cancer following an educational session.

View

Beyond the Abstracts

Neoadjuvant Fc-Enhanced Anti-CTLA-4 Targets Tregs to Augment Androgen Deprivation in High-Risk Prostate Cancer: A Randomized Phase I Trial - Beyond the Abstract

Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer - Beyond the Abstract

Conference Coverage

ASCO 2026: Radioligand Revolutions: Where We Are Now and Where We Are Going

SNMMI 2026: Survival in Veterans with Metastatic Hormone Sensitive Prostate Cancer Based on PSMA PET/CT Imaging

ASCO 2026: Quantitative Results from PSMAtrack: A Prospective Study Evaluating Change in PSMA-PET During Initial Systemic Therapy for mHSPC

AUA 2026: A Phase 3 Trial of the Androgen Receptor Ligand-directed Degrader BMS-986365 versus Investigator’s Choice in Patients with Metastatic Castration-resistant Prostate Cancer (CA071-1000 – rechARge)

APCCC 2026: Considerations for Selection of ARPIs in Older Patients with mHSPC

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Outcome after primary directed radiotherapy in predominantly PSMA-PET/CT-staged patients with metastatic prostate cancer.

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Testosterone Therapy After Radical Prostatectomy: Insights From a Systematic Review and Meta-Analysis.

Clinically Significant Prostate Cancer in Patients Undergoing Holmium Laser Enucleation of Prostate for Benign Hyperplasia: A Preoperative Nomogram and a Postoperative Surveillance Protocol.

Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice.

Longitudinal Tumor Mutation Burden Dynamics in Advanced Prostate Cancer Using Circulating Tumor DNA Profiling.

Stockholm3-Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up.

Same Target, Different Tools: A Multicenter Comparison of Clinically Significant Prostate Cancer Detection Across Three MRI-Targeted Transperineal Biopsy Techniques

NeuroSAFE-Guided Robot-Assisted Radical Prostatectomy versus Standard RARP: Systematic Review and Meta-Analysis of Comparative Studies - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Prostate Cancer Daily

Prostate Cancer

Login